Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
about
Bromocriptine for type 2 diabetes mellitusDevelopment of a Rapid Insulin Assay by Homogenous Time-Resolved FluorescenceObesity: Current and potential pharmacotherapeutics and targets.Antiobesity pharmacotherapy in the management of type 2 diabetes.Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.Current and investigational antiobesity agents and obesity therapeutic treatment targets.A randomized crossover, pilot study examining the effects of a normal protein vs. high protein breakfast on food cravings and reward signals in overweight/obese "breakfast skipping", late-adolescent girls.Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes.Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.Investigational drugs for eating disorders.Bromocriptine in type 2 diabetes mellitusNeuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR ratsRandomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adultsDoes Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study.Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesityCirculating dopamine and C-peptide levels in fasting nondiabetic hypertensive patients: the Graz Endocrine Causes of Hypertension studyBromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesityProlactin activation of the long form of its cognate receptor causes increased visceral fat and obesity in males as shown in transgenic mice expressing only this receptor subtype.Bromocriptine, a Dopamine (d2) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub-Therapeutic Doses to Ameliorate HyperglycaemiaBromocriptine and insulin sensitivity in lean and obese subjectsEfficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial.Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.Why does quick-release bromocriptine decrease cardiac events?Obesity in bipolar disorder: an overview.Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.Pharmacologic treatment of type 2 diabetes: oral medications.Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.Quantitative expression analysis of genes regulated by both obesity and leptin reveals a regulatory loop between leptin and pituitary-derived ACTH.Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.Hyperprolactinaemia as a reversible cause of weight gain in male patients?Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans.Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes.Repurposing of Bromocriptine for Cancer Therapy
P2860
Q24201924-04B14A15-8204-45CE-940E-6720D94FB3A0Q27322836-74332576-31CD-4457-BA91-B3FCF824E3C5Q30243992-F5F683DF-3E5E-4B91-B55C-370D0C2208ABQ33883725-70511AA6-F348-45E9-AE48-E2DE95CEE1FEQ33932712-3D0DFC86-AFED-4207-93D9-9B622A9FD2DDQ34344786-CE1D6599-F99C-4350-A735-9EE0EA701E34Q34598760-14C1AFCC-01B6-4290-8514-37A649590300Q34620547-E2FF8CDC-6CB0-4688-BE7F-A68A5FC20672Q34718312-E2712230-FD04-426D-A7D9-9F5C8E8E355AQ35073383-55BD2C61-8679-486C-8F22-6B997621D556Q35153082-6CC60F4C-82D4-4BC2-9955-326DFAB6D635Q35559692-913B75FC-454E-4E61-A3A6-68B76BD2C6D1Q35791125-F878739C-E357-47A7-9264-A2EF29AD3B52Q35843293-CCD5FA6C-9B29-4D55-8C1E-B8378CBF408EQ35869629-83ED7D14-49D9-4CAF-9407-B34B9B32741BQ36109106-90278F6E-302B-40CC-A2B7-5A31A56FF3F4Q37189415-F98FBBA2-4DC2-443B-A1AC-A67E4988B840Q37237603-FB02D555-BFF4-4C6A-A972-E2C754888665Q37258822-7E8BB5BF-9885-4604-BBDC-0E490F7B8063Q37396174-B8939042-06BC-47D4-81A3-22E921BA79B8Q37551483-05A6CEF6-E30A-4B73-8639-8625F2B1A929Q37661556-A397F070-8AD0-4572-8081-66F514204A93Q37875221-DCD82167-8ED7-4E78-B075-3D029D30E690Q38035727-EC7A57AF-353C-435E-89C7-35802B82D5E5Q38085727-62CE7721-8983-4E4F-92CF-2649D4FA37CEQ38113101-663A0BE3-DC20-4DCD-A9F7-7CAF584D1A56Q38350347-D1221151-FFE4-468E-9F70-C9D6165D93B3Q38378534-5E0A31C1-E8DB-46CF-8072-9E53265A6BE7Q38908684-F4058BC3-9808-4403-AD2D-D7D01C645300Q41727748-B44C8F50-28E6-477B-B552-AF31D82D88F7Q44312404-384DD1B3-0A1C-49D9-B73D-B30D53826008Q47230953-2472889C-352C-4291-8EBF-25EBE33EA8E6Q47262083-BF3A78EB-61AC-433F-BC0D-4A6D855B870DQ47285209-FB8B7B25-BF71-486B-BF8B-BCAD7A13DCE1Q49598291-D9861106-EB57-4E9F-A0B2-49B600532EF0Q51337930-E3555E14-341D-4420-8BD7-8D5F3962B957Q51343168-A53282C1-A019-41E1-B4FB-03A092FE3D9CQ51551827-88978710-CA5F-469D-8B78-0FA27943D90EQ57817601-F4E020F6-7183-45D6-B849-508E18479FC8
P2860
Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Bromocriptine (Ergoset) reduce ...... e tolerance in obese subjects.
@en
Bromocriptine
@nl
type
label
Bromocriptine (Ergoset) reduce ...... e tolerance in obese subjects.
@en
Bromocriptine
@nl
prefLabel
Bromocriptine (Ergoset) reduce ...... e tolerance in obese subjects.
@en
Bromocriptine
@nl
P356
P1433
P1476
Bromocriptine (Ergoset) reduce ...... e tolerance in obese subjects.
@en
P2093
P304
P356
10.2337/DIACARE.19.6.667
P407
P577
1996-06-01T00:00:00Z